Table 2 Demographic and clinical data of healthy controls and Parkinson’s disease cohorts.

From: Serum lipid profile among sporadic and familial forms of Parkinson’s disease

 

HCs (n = 420)

sPD (n = 250)

GBA-PD (n = 23)

LRRK2-PD (n = 27)

P value

Sex (% males)

52.14%

58.40%

73.91%

37.02

0.03**

Age (y), Mean ± SD

58.77 ± 16.09

65.92 ± 11.77

58.83 ± 11.8

63.41 ± 11.79

<0.005**

Arterial hypertension, n (%)

139 (33%)

104 (42%)

8 (35%)

8 (30%)

0.17

Diabetes, n (%)

52 (12%)

45 (18%)

1 (4%)

2 (7%)

0.08

Hyperlipidemia, n (%)

57 (14%)

47 (19%)

2 (9%)

6 (22%)

0.19

Age of onset (y), mean ± SD

56.60 ± 11.95

48.39 ± 8.87

51.65 ± 12.86

0.007*

Disease duration (y), mean ± SD

8.9 ± 6.23

10.67 ± 7.69

11.81 ± 7.06

<0.05*

Hoehn & Yahr, mean ± SD

2.26 ± 1.22

2.5 ± 0.96

1.9 ± 2.4

0.16

LEDD, mean ± SD

764.74 ± 470.14

694.25 ± 408.76

797.46 ± 579.46

0.86

  1. HCs healthy controls, LEDD levodopa equivalent daily dose, sPD sporadic Parkinson’s disease patients, GBA-PD GBA-associated Parkinson’s disease patients, LRRK2-PD LRRK2-associated Parkinson’s disease patients, SD standard deviation.
  2. *p<0.05 **p<0.005.